Lymph Node Removal Is Not the End

Preventing Lymphedema and Rebuilding Strength After Breast Cancer

Cancer rehabilitation is the structured, multidisciplinary effort to restore function, reduce treatment-related side effects, and help patients return to a meaningful quality of life after cancer therapy. Within this framework, managing lymphedema is not a side issue—it is a central pillar of recovery.

Lymphedema directly impacts mobility, strength, comfort, and daily function. Left unmanaged, it can lead to chronic swelling, tissue fibrosis, pain, and increased risk of infection. These are not isolated symptoms—they affect how a person moves, works, exercises, and even how they see themselves. For this reason, lymphedema care naturally belongs within cancer rehabilitation, where the goal is not just survival, but restoration.

A comprehensive cancer rehab model addresses multiple domains:

• Physical Function: Restoring range of motion, strength, and endurance through guided exercise and movement therapy
• Lymphatic Health: Managing fluid balance through manual lymphatic drainage, compression therapy, and monitoring
• Pain and Tissue Health: Reducing inflammation, scar restriction, and discomfort
• Neuromuscular Recovery: Rebuilding coordination and correcting compensatory movement patterns
• Psychosocial Support: Addressing identity, confidence, and the emotional toll of physical change
• Lifestyle Reintegration: Supporting return to work, activity, and independence

For men with breast cancer—who are often underrepresented in survivorship programs—this integrated approach is especially critical.

Ultimately, cancer rehabilitation reframes the journey: from simply removing disease to actively rebuilding the body. Managing lymphedema is not just about controlling swelling—it is about restoring movement, confidence, and long-term quality of life.

 

Lymphatic drainage refers to the movement of lymph fluid through the body’s lymphatic system—a network of vessels and nodes that helps remove waste, toxins, excess fluid, and supports immune function.

---

What Does the Lymphatic System Do?

Think of the lymphatic system as the body’s cleanup and filtration network. It:

• Drains excess fluid from tissues
• Filters harmful substances through lymph nodes
• Transports immune cells to fight infection
• Helps maintain fluid balance

 

Unlike the circulatory system, the lymphatic system does not have a pump like the heart. Instead, it relies on:

• Muscle movement
• Breathing
• Manual stimulation (like massage)

---

 

What Is Manual Lymphatic Drainage (MLD)?

Manual Lymphatic Drainage (MLD) is a specialized, gentle massage technique designed to stimulate and redirect lymph flow. It involves:

• Light, rhythmic hand movements
• Directional strokes toward functioning lymph nodes
• Very gentle pressure (not deep tissue massage)

The goal is to help fluid move around blocked or damaged areas, especially after lymph node removal.

---

 

Why Is Lymphatic Drainage Important in Breast Cancer?

After lymph node removal (common in breast cancer surgery), the body’s natural drainage pathways are disrupted.

 

This can lead to:

• Fluid buildup
• Swelling (lymphedema)
• Inflammation and discomfort

MLD helps:

• Reduce swelling
• Improve circulation
• Prevent progression of lymphedema
• Support healing and tissue health

---

 

Who Needs It?

Lymphatic drainage is especially important for:

• Breast cancer patients (men and women) after lymph node removal
• Patients with early or established lymphedema
• Individuals with swelling after surgery, radiation, or injury

---

 

Key Takeaway

Lymphatic drainage is not just a therapy—it’s a critical component of recovery and long-term health after cancer treatment. It supports what surgery disrupts. And when used early and consistently, it can be the difference between temporary swelling and a lifelong condition.

 

NEUROFEEDBACK 101

TAPPING INTO THE BRAIN’S CAPACITY TO RELEARN
By: Lennard M. Goetze, Ed.D

Who needs neurofeedback? According to Mark Smith of Neurofeedback Services of New York, the better question may be—who doesn’t. Neurofeedback is not reserved for a narrow diagnostic group; rather, it is designed for anyone whose brain is not operating at optimal efficiency. This includes individuals struggling with anxiety, depression, sleep disturbances, attention disorders, and cognitive decline—but it also extends to high-functioning professionals, athletes, and aging adults seeking sharper focus, emotional balance, and sustained performance. 

Smith emphasizes that many conditions we label separately—ADHD, PTSD, mood disorders, even post-treatment cognitive changes—share a common denominator: dysregulated brain activity. Neurofeedback addresses this root issue by training the brain to function more efficiently, rather than simply masking symptoms. It is particularly valuable for those who have gained insight through therapy but still feel “stuck” physiologically, as well as for patients seeking alternatives or complements to medication. Cancer survivors experiencing “chemo brain,” individuals recovering from surgery or anesthesia, and those living with chronic stress or poor sleep are also prime candidates. Even people who consider themselves “healthy” can benefit, as neurofeedback enhances the brain’s adaptability, resilience, and capacity for recovery. In Smith’s view, neurofeedback is less about treating illness and more about restoring balance—making it relevant across the entire spectrum of brain health, from dysfunction to peak performance.

Understanding Neurofeedback: A Brain Training Paradigm
From Smith’s perspective, neurofeedback is best understood as a conditioning system for the brain. Much like physical exercise strengthens muscles, neurofeedback strengthens neural efficiency. The process involves monitoring the brain’s electrical activity in real time and providing subtle feedback—often in the form of sound—when the brain produces desired patterns. Over time, the brain learns to repeat these patterns independently.

Smith emphasizes that this is not invasive, nor is it dependent on pharmaceuticals. Instead, it leverages the brain’s innate ability to adapt—its neuroplasticity. By reinforcing healthier activity patterns, neurofeedback enables the brain to function more fluidly, efficiently, and responsively.

The Brain: The Overlooked Master Organ
One of Smith’s most striking assertions is that the brain has historically been “left behind” in healthcare. Despite being the master regulator of all physiological processes, it is often treated indirectly—through medications or symptom-based interventions—rather than being trained directly.

According to Smith, when the brain is not functioning optimally, the consequences cascade across the body:

• Emotional instability (anxiety, depression)
• Cognitive inefficiency (poor focus, memory lapses)
• Sleep disruption
• Reduced adaptability to stress

Neurofeedback addresses these issues at their source by improving the brain’s ability to regulate itself.

How It Works: Conditioning Through Feedback
The mechanism is elegantly simple. During a session:

1.   The brain’s electrical activity is monitored.

2.   The system detects when the brain produces a target pattern.

3.   A reward signal—often auditory—is delivered.

4.   The brain gradually learns to reproduce that pattern more consistently.

This process mirrors classical conditioning but operates at a neurological level. Over repeated sessions, the brain internalizes these patterns, leading to sustained improvements in function.

Importantly, Smith compares neurofeedback to a “library”—not a single technique but a collection of approaches. Different protocols target different systems within the brain, allowing practitioners to tailor interventions based on individual needs.

Diagnostics First: The Role of QEEG
Smith underscores the importance of quantitative electroencephalography (QEEG) as a starting point. This brain mapping tool identifies patterns of dysregulation, helping practitioners determine:

·     Which areas of the brain are underperforming

·     Which neural networks are overactive

·     What types of interventions are most appropriate

This diagnostic phase allows neurofeedback to move beyond guesswork and into precision-guided brain training.

Regulating the Autonomic Nervous System
A key focus of Smith’s work is the autonomic nervous system—the balance between:

·     Sympathetic activity (fight-or-flight, alertness)

·     Parasympathetic activity (rest-and-digest, recovery)

Using specific neurofeedback techniques, such as (ISF) Infraslow Frequency Training, Smith aims to reduce excessive sympathetic drive while enhancing parasympathetic function.

This has profound implications for:

·     Sleep quality

·     Stress resilience

·     Emotional regulation

Patients who struggle with racing thoughts, chronic anxiety, or insomnia often benefit from this recalibration, as the brain learns to transition more effectively into restorative states.

Beyond Mental Health: A Whole-Body Impact
While neurofeedback is often associated with psychological conditions, Smith challenges this narrow view. He describes it as a global regulatory tool that influences the entire body.

Applications include:

·     Anxiety and depression

·     ADHD and attention disorders

·     Autism spectrum conditions

·     Cognitive decline and aging

·     Post-surgical recovery (especially after anesthesia)

In surgical contexts, Smith highlights a particularly innovative application: training the brain before and after procedures to mitigate the neurological impact of anesthesia and accelerate recovery. This “sandwich” approach enhances the brain’s ability to return to baseline functioning more quickly.

Bridging the Gap between Insight and Physiology
Smith also identifies a critical limitation in traditional psychotherapy: insight alone does not change physiology.

Patients may understand the root of their anxiety or trauma, yet still experience the same physical responses. Neurofeedback fills this gap by aligning physiological regulation with cognitive awareness.

Therapists often observe that patients undergoing neurofeedback:

·     Open up more

·     Process deeper emotional material

·     Maintain stability during difficult discussions

This integration of mind and body represents what Smith describes as a more complete approach to healing.

Neurofeedback and Performance Optimization
Beyond pathology, neurofeedback also enhances performance. By improving neural efficiency, individuals may experience:

·     Sharper focus

·     Faster processing speed

·     Greater emotional resilience

·     Enhanced adaptability in high-demand environments

Smith notes that even individuals without diagnosable conditions can benefit—making neurofeedback as relevant for optimization as it is for recovery.

Redefining Outcomes: From Cure to Function
When discussing outcomes, Smith is careful to avoid the language of “cure.” Instead, he reframes success as functional improvement.

Patients may not return to a previous state of being, but they can achieve a level of performance where symptoms no longer dominate their lives. In many cases, individuals report that issues such as cognitive fog or intrusive symptoms fade into the background—becoming noticeable only when brought to attention.

This shift from eradication to adaptation and resilience reflects a more realistic and sustainable model of brain health.

A New Frontier in Brain-Based Care
Mark Smith’s perspective positions neurofeedback at the intersection of neuroscience, rehabilitation, and performance medicine. It is not merely a treatment modality, but a framework for retraining the brain—one that acknowledges the brain’s central role in every aspect of human function.

In an era where healthcare is increasingly focused on precision, personalization, and non-invasive solutions, neurofeedback stands out as a powerful tool for harnessing the brain’s natural capacity to heal, adapt, and evolve.

 

 

PART 2:

On QEEG, Neurofeedback and the Future of Brain-Based Recovery

By: Robert L. Bard, MD

From my perspective as a diagnostic imaging specialist, I have always believed in one guiding principle—if you can see it, you can understand it; if you can measure it, you can manage it. This philosophy has shaped my work in cancer imaging, trauma care, and chronic disease. Today, I see that same principle extending powerfully into the brain through QEEG and neurofeedback.

For decades, we have focused heavily on identifying and treating structural disease—tumors, vascular abnormalities, tissue damage. But what about function? What about the brain’s performance after chemotherapy, after trauma, or during chronic illness? These are areas where traditional imaging has limitations. That is why QEEG is so compelling to me. It gives us a quantifiable, visual map of brain activity, allowing us to identify inefficiencies that would otherwise remain invisible.

In my work with cancer patients, I have seen firsthand how treatment can leave behind a neurological footprint. Patients describe brain fog, memory lapses, emotional instability—what many call “chemo brain.” Historically, these symptoms have been difficult to measure and even harder to treat. With QEEG, we now have the ability to track these changes objectively, much like we track blood flow with Doppler or tissue stiffness with elastography.

My experience with neurofeedback has been equally eye-opening. I view it as a form of functional rehabilitation for the brain. It is not about replacing conventional medicine—it is about enhancing it. We are training the brain to operate more efficiently, to regulate itself better, and to restore balance across multiple systems. I have seen improvements in sleep, focus, emotional control, and overall resilience.

In trauma patients, this is especially meaningful. Physical healing is only part of the equation. The brain often remains in a heightened state of stress, affecting recovery and quality of life. Neurofeedback offers a way to recalibrate that system—to help patients move out of survival mode and into a more stable, restorative state.

I am also a strong advocate for non-invasive and energy-based therapies—approaches that support the body without adding further burden. Neurofeedback fits perfectly within that model. It is safe, measurable, and aligned with the direction modern medicine must take: precision, personalization, and continuous monitoring.

What I find particularly valuable about the work of Mark Smith is that it brings together accessibility and accuracy. This is not an abstract concept—it is a practical, affordable solution that can be implemented across a wide range of patients. It empowers individuals to participate in their own recovery, reinforcing the concept of active surveillance that I have long championed.

Ultimately, I see QEEG and neurofeedback as part of the next evolution in healthcare—a shift toward information-driven, function-focused medicine. We are no longer limited to asking whether a disease is present. We can now ask how well the brain is performing, how it is adapting, and how we can optimize it.

This is not just innovation. This is the future of comprehensive care.

 

 

 

 

 

 

 

 

Clear Review of the Scrambler Therapy

 

HEALTHTECH REPORTER ESSENTIALS:

Clear Review of the Scrambler Therapy

Dr. Jason Cooney describes Scrambler Therapy as a non-invasive neuromodulation technology designed to treat chronic neuropathic pain by interrupting and retraining abnormal pain signaling pathways in the nervous system. Rather than masking pain with medications or targeting inflammation directly, the therapy delivers controlled electrical signals through the skin to replace pain messages with non-pain information, effectively “rebooting” how the brain perceives pain.

What distinguishes Scrambler Therapy from conventional electrical stimulation devices is the proprietary algorithm behind its signal delivery. The system generates a constantly vacillating and dynamically changing electrical waveform, rather than a fixed or repetitive frequency. Traditional stimulation devices allow clinicians to adjust frequency or intensity, but once set, those signals remain constant. In contrast, Scrambler Therapy continuously varies its signal pattern. According to Dr. Cooney, this prevents the brain from adapting or compensating for the stimulus. Because the signal is always changing, the nervous system remains responsive and “listens” to the incoming information rather than habituating to it. This adaptive signaling is central to the therapy’s ability to disrupt entrenched pain patterns.

From a neurophysiological standpoint, Scrambler Therapy primarily targets C fibers, the unmyelinated sensory nerve fibers that transmit chronic pain signals from the skin to the central nervous system. The therapy delivers non-pain electrical information to these fibers, which then travel along the spinothalamic tract to the cerebral cortex. By repeatedly replacing pain messages with non-pain signals, the brain is gradually retrained to reinterpret sensory input from the affected region. Over time, this process can reduce or eliminate the perception of chronic pain. Dr. Cooney characterizes this process as a form of neural “rebooting,” in which maladaptive pain signaling is overwritten by new, non-painful input.

Clinically, Scrambler Therapy has been most extensively studied and applied in patients with Complex Regional Pain Syndrome (CRPS) and chemotherapy-induced peripheral neuropathy (CIPN). Dr. Cooney notes that the majority of patients treated in clinical practice fall into these two categories, with CRPS representing the primary indication and CIPN comprising a significant secondary group. In patients with chemotherapy-induced neuropathy, Scrambler Therapy often produces meaningful reductions in pain. However, Dr. Cooney observes that numbness and tingling may be less responsive in some individuals, particularly when nerve damage or demyelination is severe or irreversible. While pain can be significantly improved, sensory deficits may persist in certain cases due to underlying structural nerve injury.

Dr. Cooney emphasizes that Scrambler Therapy is most effective for neuropathic pain that is not caused by ongoing mechanical compression or structural pathology. For example, patients with degenerative spinal conditions involving active nerve compression may experience temporary pain relief during treatment, but symptoms are likely to return if the underlying mechanical cause is not addressed. In contrast, neuropathic pain resulting from stroke, infection, surgery, chemotherapy, or chronic neurological injury may respond more favorably when the original insult is no longer actively damaging the nerve tissue. In these cases, Scrambler Therapy can help interrupt persistent pain signaling that remains long after the initial injury has healed.

One of the defining advantages of Scrambler Therapy, according to Dr. Cooney, is its non-invasive nature and favorable safety profile. The treatment does not involve injections, surgery, implanted devices, or pharmaceuticals. He highlights that the therapy is well tolerated and associated with minimal risk, making it suitable even for pediatric populations. In his clinical experience, children and adolescents with CRPS—who represent a notable portion of CRPS cases—have shown dramatic functional improvements following treatment. Dr. Cooney recounts cases in which young patients arrived dependent on crutches and unable to attend school, only to regain mobility and return to daily activities within weeks. He underscores that the absence of medication-related side effects is particularly important in younger patients, where long-term pharmaceutical management carries significant risks.

Dr. Cooney also places Scrambler Therapy within a growing body of clinical research and international adoption. The technology has been in clinical use for more than a decade and is now available in multiple countries, including the United States, Germany, and Italy. While early adoption relied heavily on anecdotal clinical success, Dr. Cooney notes that the therapy is increasingly supported by formal studies conducted at major academic and clinical institutions. This expanding research base has helped move Scrambler Therapy beyond experimental or fringe status toward broader clinical legitimacy within pain medicine.

Despite its demonstrated benefits, Dr. Cooney is careful to acknowledge current limitations in objective outcome measurement. Clinical improvements are typically assessed using patient-reported pain scales, which, while meaningful to patients, remain subjective measures. He recognizes the need for more objective validation methods and welcomes efforts to pair clinical outcomes with measurable physiological or imaging-based biomarkers. Establishing quantifiable evidence of neurological or tissue-level change, he notes, would further strengthen the medical community’s confidence in neuromodulation-based pain therapies such as Scrambler.

In summary, Dr. Cooney presents Scrambler Therapy as a clinically validated, non-invasive neuromodulation approach that addresses chronic neuropathic pain by retraining how the brain processes sensory information. Through dynamically changing electrical signals delivered to peripheral nerve fibers, the therapy disrupts maladaptive pain messaging and replaces it with non-pain input, enabling meaningful functional recovery in conditions such as CRPS and chemotherapy-induced neuropathy.

 

SEE PART 1 OF THIS STORY

Scrambler Therapy and the Clinical Work of Dr. Jason Cooney

Reframing Chronic Neuropathic Pain Through Non-Invasive Neuromodulation

 

By: Lennard M. Goetze, Ed.D

 

Chronic neuropathic pain remains one of the most difficult clinical challenges in modern medicine. Patients with conditions such as Complex Regional Pain Syndrome (CRPS), chemotherapy-induced peripheral neuropathy (CIPN), and idiopathic neuropathy often cycle through medications, injections, and procedures with limited or short-lived benefit. Within this therapeutic gap, Scrambler Therapy (also known as Calmare® Therapy) has emerged as a non-invasive neuromodulation approach designed to interrupt maladaptive pain signaling and restore functional quality of life.

 

At the forefront of this clinical application in the New York–New Jersey region is Dr. Jason Cooney, DC, Clinical Director at Scrambler Therapy NJ. With more than two decades of experience in chiropractic rehabilitation and physiotherapy, Dr. Cooney has focused his practice on patients whose pain has persisted despite conventional care. Trained by his father, Dr. Michael Cooney, DC—an early adopter and national educator in Calmare Therapy—Dr. Cooney represents a second generation of clinicians committed to advancing non-pharmacologic, evidence-informed pain management.

How Scrambler Therapy Works

Scrambler Therapy is an FDA-cleared medical device designed to treat neuropathic pain by altering how the nervous system encodes pain information. Unlike conventional electrical stimulation used in physical therapy (e.g., TENS), the Scrambler system uses multiple proprietary signal patterns that change continuously during treatment sessions. These variable waveforms are intended to prevent neural adaptation and maintain effective communication with sensory nerve fibers.

 

Electrode pads are placed strategically along dermatomal distributions above and below the region of pain rather than directly on the most painful site. The device transmits non-painful signals primarily through small sensory fibers that project to the spinal cord and onward to higher pain-processing centers. Over repeated sessions, these signals aim to replace persistent “danger” messages with neutral or corrective input, reducing the brain’s tendency to perpetuate a chronic pain loop.

Clinically, the approach is grounded in the understanding that chronic pain is not solely a peripheral tissue problem; it is also a learned neural pattern that can become reinforced over time. By providing consistent, non-threatening sensory input, Scrambler Therapy seeks to recalibrate pain pathways that remain locked in a heightened state of reactivity.

 

Clinical Indications and Limitations

Dr. Cooney reports the strongest outcomes in patients with neuropathic pain syndromes, particularly CRPS and CIPN. These conditions often involve abnormal neuroinflammatory responses and maladaptive sensory processing following injury, surgery, or chemotherapy exposure. In these populations, Scrambler Therapy has demonstrated meaningful reductions in pain intensity for a substantial proportion of patients, often enabling improvements in sleep, mobility, and daily function.

 

However, the therapy is not positioned as a universal solution for all pain. Structural conditions such as severe spinal stenosis, advanced degenerative disease, or mass-occupying lesions fall outside its therapeutic scope. Because Scrambler Therapy does not correct biomechanical compression or tissue destruction, patient selection and diagnostic clarity are essential. Dr. Cooney emphasizes that the therapy is best viewed as a neurofunctional intervention—one that targets dysfunctional signaling rather than structural pathology.

 

Treatment Protocol and Patient Experience

A standard course of Scrambler Therapy typically involves daily sessions over a two-week period, with each visit lasting approximately one hour. Patients do not experience painful stimulation during treatment; instead, they describe mild tingling or tapping sensations. Early sessions may provide only temporary relief lasting hours, but cumulative exposure often extends the duration of symptom reduction. In some cases, patients experience prolonged remission, while others benefit from periodic “booster” sessions to maintain gains.

 

For individuals whose pain has limited activity, the reduction in discomfort can create an opening for functional rehabilitation. Dr. Cooney integrates Scrambler Therapy within a broader care model that includes chiropractic methods, physiotherapy, and movement-based recovery strategies. As pain diminishes, patients are more capable of re-engaging in mobility work and strength conditioning, indirectly supporting muscular recovery that had been hindered by chronic pain.

 

Research Context and Institutional Adoption

While early skepticism often accompanies novel neuromodulation technologies, Scrambler Therapy has gradually gained traction within academic and hospital settings. Clinical evaluations conducted by major medical centers have contributed to growing acceptance of the modality for neuropathic pain syndromes. The device itself was developed in Italy and refined through international clinical collaboration, with training programs disseminated across Europe and the United States.

 

Institutional interest is also expanding within veteran health systems, where neuropathy related to toxic exposures and injury presents a persistent care challenge. This broader uptake reflects a shift toward integrative pain models that prioritize non-opioid, non-surgical interventions when appropriate.

 

A Patient-Centered Clinical Ethos

Dr. Cooney’s clinical identity centers on compassionate, personalized care for patients who have exhausted conventional options. His practice frequently receives referrals from major medical centers, underscoring the role of Scrambler Therapy as a complementary option within multidisciplinary pain management. Beyond individual care, he advocates for responsible education among clinicians, emphasizing that device-based therapies must be applied with neurological understanding and careful patient screening.

 

In an era marked by opioid fatigue and growing awareness of neuroplastic pain mechanisms, Scrambler Therapy represents a targeted attempt to “reset” maladaptive signaling rather than merely suppress symptoms. While not curative for every patient, the approach reflects a broader clinical movement: reframing chronic pain as a modifiable neurobiological process and expanding the toolkit of non-invasive interventions available to clinicians and patients alike.

 

  

PART 2 —

FROM “PAIN” TO THE MEASURABLE:

Why Non-Invasive Energy Therapies Are Reshaping Modern Care

By Dr. Robert Bard, MD, DABR, FAIUM, FASLMS

When I read Dr. Jason Cooney’s account of Scrambler Therapy, what stood out wasn’t only the “wow” stories—though those matter—it was the clinical logic behind why this category of care is expanding. Scrambler Therapy (Calmare®) is part of a broader movement toward non-invasive, energy-based and neuromodulation therapies that aim to reduce symptoms while avoiding the risk, recovery, and downstream complications associated with procedures and long-term drug dependence. In 2026, this isn’t a fringe trend; it’s a practical response to a persistent problem: chronic neuropathic suffering that too often outlives the standard toolbox.

Here’s the pivotal reframing I advocate: we should talk less about pain as a vague sensation and more about inflammation, neural signaling dysfunction, and maladaptive neuroplasticity—because those are closer to what we can evaluate, monitor, and validate. “Pain” is real, but it is also subjective. Inflammation and neurologic dysregulation are the measurable terrain underneath many pain syndromes, especially neuropathic conditions.

Scrambler Therapy exemplifies this shift. The mechanism isn’t about “blocking” discomfort—it’s about modulating the information stream carried by sensory fibers and processed centrally. A phase II randomized trial comparing Scrambler Therapy to TENS in chemotherapy-induced peripheral neuropathy (CIPN) reported better outcomes for Scrambler in that setting, supporting the concept that not all “electrostim” is created equal. Earlier clinical research also suggested Scrambler could outperform guideline-based drug management for certain chronic neuropathic pain states. Reviews describe Scrambler as a non-invasive method intended to reorganize maladaptive pain signaling pathways—exactly the direction modern neuro-therapeutics is heading.

To review, the vast market of non-invasive energy therapies includes:

·        Scrambler Therapy (Calmare®):
A specialized neuromodulation system that delivers continuously varied signal patterns designed to disrupt chronic pain encoding. Unlike fixed waveform TENS, Scrambler’s algorithmic variability aims to prevent nerve adaptation and promote longer-lasting reductions in pain intensity, particularly in neuropathic syndromes such as CRPS and chemotherapy-induced peripheral neuropathy.

· Pulsed Electromagnetic Field (PEMF) Therapy:
PEMF applies pulsating magnetic fields to tissues to influence cellular behavior. Research suggests potential benefits in pain reduction, improved blood flow, and reduced inflammation for conditions ranging from osteoarthritis to soft-tissue injury. Because it affects tissues at the cellular level, PEMF is frequently integrated into rehabilitation and chronic pain clinics.

·        Shockwave Therapy:
Shockwave uses focused high-amplitude acoustic waves to deliver mechanical energy deep into musculoskeletal tissues. Originally developed for urology, therapeutic shockwave promotes neovascularization, cellular regeneration, collagen remodeling, and reduction of chronic inflammation in tendon, ligament, and muscle structures. Clinically, it has shown efficacy for plantar fasciitis, Achilles tendinopathy, and chronic myofascial pain syndromes. Shockwave is non-invasive, typically requires only a few outpatient sessions, and often leads to measurable functional gains.

·       Photobiomodulation (Low-Level Laser / Red Light Therapy): Light at specific wavelengths can penetrate into tissues, triggering biochemical cascades that reduce oxidative stress and inflammatory mediators. Studies have reported reductions in joint pain, improved tissue healing rates, and improved outcomes in soft-tissue injury.

·        High-Intensity Focused Electromagnetic (HIFEM) and Radiofrequency Devices:
These platforms use electrical or thermal energy to stimulate deep tissues, sometimes with neuromuscular engagement. While originally developed for aesthetic or muscle-toning purposes, some applications show promise in rehabilitative and pain-related contexts due to improved circulation and neuromuscular normalization.

·        Ultrasound-Guided Neuromodulation:
A growing frontier, using focused ultrasound waves to target deep nervous structures and modulate pain pathways with precision. Clinical trials are underway exploring applications in chronic back pain, peripheral neuropathy, and even central neuromodulation.

·        TENS (Transcutaneous Electrical Nerve Stimulation): Large evidence syntheses report moderate-certainty evidence that pain intensity is lower during or immediately after TENS compared with placebo, with a strong safety profile. In neuropathic pain specifically, recent meta-analytic work suggests TENS may reduce pain to a modest degree, with evidence quality varying by condition and study design.

Why is the trend accelerating? Because many pharmacologic options for neuropathic pain deliver only modest efficacy across heterogeneous patient populations, leaving clinicians and patients searching for better pathways. Non-invasive energy therapies offer a rational alternative: reduce symptom load, calm the nervous system, and restore function—often without adding systemic side effects.

My position is simple: non-invasive matters because it lowers barriers to care, reduces cumulative risk, and invites objective monitoring. The future belongs to therapies that are not only effective, but verifiable. That means pairing these interventions with measurable endpoints—functional testing, neurovascular assessment, imaging-guided monitoring, and physiologic biomarkers—so we can show what is changing, not just hear that it “feels better.”

That’s the real promise here: a new standard where chronic “pain” is approached as a treatable, trackable neuro-inflammatory condition—and where the best technologies win because they can demonstrate outcomes, not because they make the loudest claims.

 

References:

American Academy of Neurology. (2019). A comprehensive algorithm for the management of neuropathic pain: Best practice recommendations. Pain Medicine. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544553/ — This guideline article reviews evidence-based approaches for neuropathic pain and contextualizes treatment strategies spanning pharmacologic and neuromodulation therapies.

Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., … Wallace, M. S. (2003). Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Archives of Neurology, 60(11), 1524–1534. https://doi.org/10.1001/archneur.60.11.1524 — A foundational overview of neuropathic pain mechanisms and clinical management strategies, widely referenced in clinical pain literature.

Mayo Clinic. (n.d.). Peripheral neuropathy: Diagnosis and treatment. Retrieved from https://www.mayoclinic.org/diseases-conditions/peripheral-neuropathy/diagnosis-treatment/drc-20352067 — Mayo Clinic describes Scrambler Therapy as an option that uses electrical impulses to send non-painful signals to the brain, aiming to retrain pain perception.

Mayo Clinic. (n.d.). Scrambler Therapy in treating pain and peripheral neuropathy in patients previously treated with chemotherapy [Clinical trial summary]. Retrieved from https://www.mayo.edu/research/clinical-trials/cls-20116107 — Details a clinical trial evaluating Scrambler Therapy for chemotherapy-induced peripheral neuropathy.

Mayo Clinic. (n.d.). A study comparing Scrambler Therapy versus TENS therapy in treating patients with chemotherapy-induced peripheral neuropathy. Retrieved from https://www.mayo.edu/research/clinical-trials/cls-20199631 — This randomized clinical trial compares Scrambler Therapy with conventional TENS therapy for neuropathy symptoms.

Marineo, G. (2016). Scrambler Therapy for the management of chronic pain. Pain Management, 6(2), 12–20. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973603/ — A review of Scrambler Therapy mechanisms and early clinical evidence supporting its use in chronic pain syndromes.

National Cancer Institute. (n.d.). Chemotherapy-induced peripheral neuropathy. Retrieved from https://en.wikipedia.org/wiki/Chemotherapy-induced_peripheral_neuropathy — Overview of CIPN’s clinical impact and prevalence among patients receiving chemotherapeutic agents.

 

Copyright Notice

© 2026 AngioInstitute – Institute for Global Health Innovations. All rights reserved. This work and all materials contained herein are the intellectual property of AngioInstitute (Institute for Global Health Innovations) and its authorized contributors. No part of this manuscript may be reproduced, stored in a retrieval system, transmitted, distributed, or shared in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior written permission from the publisher. All content is protected under applicable United States and international copyright, trademark, and intellectual property laws. Any trademarks, service marks, product names, or company names referenced herein are the property of their respective owners and are used for identification purposes only. This publication is provided for educational and informational purposes only and does not constitute medical, legal, or professional advice. Clinical decisions should be made in consultation with qualified healthcare professionals. The AngioInstitute does not assume liability for the application or misuse of any information contained herein.